A repost points to a roundup of upcoming weight loss drugs, including ones that combine several hormone signals in a single treatment.
Recap by typeshit. Post by Facebook on Facebook.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
He says GLP-1s help people with obesity, but taking tirzepatide just to get lean brought him dizziness, low intake and declining gym performance.
An investor post lists the planned lineup, from sermorelin and NAD+ to BPC-157, with Hims now taking email signups ahead of launch.
Loading…